Common Stock, Shares, Outstanding of CRISPR Therapeutics AG from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Summary
CRISPR Therapeutics AG quarterly Common Stock, Shares, Outstanding in shares history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • CRISPR Therapeutics AG Common Stock, Shares, Outstanding for the quarter ending 31 Dec 2025 was 95,894,341, a 12% increase year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares, Outstanding, Quarterly (shares)
Common Stock, Shares, Outstanding, YoY Quarterly Change (%)

CRISPR Therapeutics AG Quarterly Common Stock, Shares, Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 95,894,341 +10,152,360 +12% 31 Dec 2025 10-K 12 Feb 2026 2025 FY
Q3 2025 93,872,794 +8,537,018 +10% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 88,376,439 +3,330,938 +3.9% 30 Jun 2025 10-Q 04 Aug 2025 2025 Q2
Q1 2025 86,360,924 +1,523,314 +1.8% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 85,741,981 +5,697,603 +7.1% 31 Dec 2024 10-K 12 Feb 2026 2025 FY
Q3 2024 85,335,776 +5,909,028 +7.4% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 85,045,501 +5,673,135 +7.1% 30 Jun 2024 10-Q 05 Aug 2024 2024 Q2
Q1 2024 84,837,610 +5,973,876 +7.6% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 80,044,378 +1,531,928 +2% 31 Dec 2023 10-K 11 Feb 2025 2024 FY
Q3 2023 79,426,748 +1,178,918 +1.5% 30 Sep 2023 10-Q 06 Nov 2023 2023 Q3
Q2 2023 79,372,366 +1,580,203 +2% 30 Jun 2023 10-Q 07 Aug 2023 2023 Q2
Q1 2023 78,863,734 +1,477,329 +1.9% 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 78,512,450 +1,522,384 +2% 31 Dec 2022 10-K 21 Feb 2024 2023 FY
Q3 2022 78,247,830 +1,784,650 +2.3% 30 Sep 2022 10-Q 01 Nov 2022 2022 Q3
Q2 2022 77,792,163 +1,713,710 +2.3% 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 77,386,405 +1,655,777 +2.2% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 76,990,066 +3,075,222 +4.2% 31 Dec 2021 10-K 21 Feb 2023 2022 FY
Q3 2021 76,463,180 +5,859,318 +8.3% 30 Sep 2021 10-Q 03 Nov 2021 2021 Q3
Q2 2021 76,078,453 +13,525,948 +22% 30 Jun 2021 10-Q 29 Jul 2021 2021 Q2
Q1 2021 75,730,628 +14,840,593 +24% 31 Mar 2021 10-Q 27 Apr 2021 2021 Q1
Q4 2020 73,914,844 +13,131,045 +22% 31 Dec 2020 10-K 15 Feb 2022 2021 FY
Q3 2020 70,603,862 +15,414,492 +28% 30 Sep 2020 10-Q 28 Oct 2020 2020 Q3
Q2 2020 62,552,505 +9,053,448 +17% 30 Jun 2020 10-Q 27 Jul 2020 2020 Q2
Q1 2020 60,890,035 +8,254,390 +16% 31 Mar 2020 10-Q 28 Apr 2020 2020 Q1
Q4 2019 60,783,799 +8,930,937 +17% 31 Dec 2019 10-K 16 Feb 2021 2020 FY
Q3 2019 55,189,370 +3,634,891 +7.1% 30 Sep 2019 10-Q 28 Oct 2019 2019 Q3
Q2 2019 53,499,057 +6,427,222 +14% 30 Jun 2019 10-Q 29 Jul 2019 2019 Q2
Q1 2019 52,635,645 +5,954,830 +13% 31 Mar 2019 10-Q 29 Apr 2019 2019 Q1
Q4 2018 51,852,862 +11,260,614 +28% 31 Dec 2018 10-K 12 Feb 2020 2019 FY
Q3 2018 51,554,479 +11,172,625 +28% 30 Sep 2018 10-Q 07 Nov 2018 2018 Q3
Q2 2018 47,071,835 +7,032,420 +18% 30 Jun 2018 10-Q 07 Aug 2018 2018 Q2
Q1 2018 46,680,815 31 Mar 2018 10-Q 08 May 2018 2018 Q1
Q4 2017 40,592,248 +872,814 +2.2% 31 Dec 2017 10-K 25 Feb 2019 2018 FY
Q3 2017 40,381,854 +35,074,009 +661% 30 Sep 2017 10-Q 08 Nov 2017 2017 Q3
Q2 2017 40,039,415 30 Jun 2017 10-Q 10 Aug 2017 2017 Q2
Q4 2016 39,719,434 +34,191,355 +619% 31 Dec 2016 10-K 08 Mar 2018 2017 FY
Q3 2016 5,307,845 30 Sep 2016 10-Q 22 Nov 2016 2016 Q3
Q4 2015 5,528,079 31 Dec 2015 10-K 10 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.